TY - JOUR
T1 - Strength
T2 - A relevant link to functional performance in the neurodegenerative disease of adrenomyeloneuropathy
AU - Keller, Jennifer L.
AU - Wang, Joseph I.
AU - Kang, Jonathan Y.
AU - Hanson, Joseph A.
AU - Kamath, Priya
AU - Swain, Jennifer O.
AU - Raymond, Gerald V.
AU - Zackowski, Kathleen M.
PY - 2012/11
Y1 - 2012/11
N2 - Background. With progressive abnormalities in leg strength, tone, and sensation, adrenomyeloneuropathy (AMN) is a differential diagnosis for multiple sclerosis and hereditary spastic paraparesis. AMN pathology has been linked to weakness, making it a relevant model to evaluate the relationship between neurodegeneration and disability. Quantifying symptom severity in AMN is essential for treatment development in rehabilitative management. Objective. To identify deficits in body functions, activity, and participation of people with AMN and provide a practical framework for evaluating the severity of disability. Methods. Cohort analysis of 142 participants with AMN. Measures of body functions (leg strength, vibration sensation, range of motion, and spasticity), activity (walk velocity, standing balance, Timed Up and Go, and Sit-to-Stand Time), and participation (6-Minute Walk) are evaluated. Regression analyses identify relationships between the measures. A staging framework (mild, moderate, and severe) reflects the continuum of disability. Finally, an analysis of variance/Kruskal-Wallis was used for between-stage and sex differences among the variables. Results. Strength is the strongest correlate for the 5 measures of activity and participation. Staging based on weakness distinguishes 3 levels of severity along a continuum of disability. Differences between the sexes are more prevalent earlier in the continuum but show equally severe deficits in the last stage. Conclusions. In AMN, staging based on degrees of weakness provides a practical means to characterize the severity of common deficits in body functions as well as activity and participation at each stage, to direct the evaluation. Such information could help clinicians develop more effective rehabilitative techniques.
AB - Background. With progressive abnormalities in leg strength, tone, and sensation, adrenomyeloneuropathy (AMN) is a differential diagnosis for multiple sclerosis and hereditary spastic paraparesis. AMN pathology has been linked to weakness, making it a relevant model to evaluate the relationship between neurodegeneration and disability. Quantifying symptom severity in AMN is essential for treatment development in rehabilitative management. Objective. To identify deficits in body functions, activity, and participation of people with AMN and provide a practical framework for evaluating the severity of disability. Methods. Cohort analysis of 142 participants with AMN. Measures of body functions (leg strength, vibration sensation, range of motion, and spasticity), activity (walk velocity, standing balance, Timed Up and Go, and Sit-to-Stand Time), and participation (6-Minute Walk) are evaluated. Regression analyses identify relationships between the measures. A staging framework (mild, moderate, and severe) reflects the continuum of disability. Finally, an analysis of variance/Kruskal-Wallis was used for between-stage and sex differences among the variables. Results. Strength is the strongest correlate for the 5 measures of activity and participation. Staging based on weakness distinguishes 3 levels of severity along a continuum of disability. Differences between the sexes are more prevalent earlier in the continuum but show equally severe deficits in the last stage. Conclusions. In AMN, staging based on degrees of weakness provides a practical means to characterize the severity of common deficits in body functions as well as activity and participation at each stage, to direct the evaluation. Such information could help clinicians develop more effective rehabilitative techniques.
UR - http://www.scopus.com/inward/record.url?scp=84867289319&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867289319&partnerID=8YFLogxK
U2 - 10.1177/1545968312441682
DO - 10.1177/1545968312441682
M3 - Article
C2 - 22544816
AN - SCOPUS:84867289319
SN - 1545-9683
VL - 26
SP - 1080
EP - 1088
JO - Neurorehabilitation and Neural Repair
JF - Neurorehabilitation and Neural Repair
IS - 9
ER -